682 related articles for article (PubMed ID: 24651010)
1. Dragging ras back in the ring.
Stephen AG; Esposito D; Bagni RK; McCormick F
Cancer Cell; 2014 Mar; 25(3):272-81. PubMed ID: 24651010
[TBL] [Abstract][Full Text] [Related]
2. Regulators and effectors of ras proteins.
Bollag G; McCormick F
Annu Rev Cell Biol; 1991; 7():601-32. PubMed ID: 1667084
[No Abstract] [Full Text] [Related]
3. Downregulation of Ras C-terminal processing by JNK inhibition.
Mouri W; Tachibana K; Tomiyama A; Sunayama J; Sato A; Sakurada K; Kayama T; Kitanaka C
Biochem Biophys Res Commun; 2008 Jun; 371(2):273-7. PubMed ID: 18435909
[TBL] [Abstract][Full Text] [Related]
4. GTP-GDP exchange proteins.
Levitzki A
Science; 1990 May; 248(4957):794. PubMed ID: 2188357
[No Abstract] [Full Text] [Related]
5. Direct Attack on RAS: Intramolecular Communication and Mutation-Specific Effects.
Marcus K; Mattos C
Clin Cancer Res; 2015 Apr; 21(8):1810-8. PubMed ID: 25878362
[TBL] [Abstract][Full Text] [Related]
6. [ras p21/ras p21-like small G proteins and their regulatory proteins].
Isomura M; Kawata M; Takai Y
Nihon Rinsho; 1990 Aug; 48(8):61-70. PubMed ID: 2123950
[No Abstract] [Full Text] [Related]
7. Vav cooperates with Ras to transform rodent fibroblasts but is not a Ras GDP/GTP exchange factor.
Bustelo XR; Suen KL; Leftheris K; Meyers CA; Barbacid M
Oncogene; 1994 Aug; 9(8):2405-13. PubMed ID: 8036025
[TBL] [Abstract][Full Text] [Related]
8. The RIN family of Ras effectors.
Bliss JM; Venkatesh B; Colicelli J
Methods Enzymol; 2006; 407():335-44. PubMed ID: 16757336
[TBL] [Abstract][Full Text] [Related]
9. Targeting Mutant KRAS for Anticancer Therapy.
Chen F; Alphonse MP; Liu Y; Liu Q
Curr Top Med Chem; 2019; 19(23):2098-2113. PubMed ID: 31475898
[TBL] [Abstract][Full Text] [Related]
10. Structural effects of the binding of GTP to the wild-type and oncogenic forms of the ras-gene-encoded p21 proteins.
Monaco R; Chen JM; Friedman FK; Brandt-Rauf P; Chung D; Pincus MR
J Protein Chem; 1995 Nov; 14(8):721-9. PubMed ID: 8747433
[TBL] [Abstract][Full Text] [Related]
11. trans-Dominant suppressor mutations of the H-ras oncogene.
Ogiso Y; Gutierrez L; Wrathall LS; Lu YY; Blair DG; Clanton DJ; Hwang YW; Shih TY
Cell Growth Differ; 1990 May; 1(5):217-24. PubMed ID: 2150753
[TBL] [Abstract][Full Text] [Related]
12. Exploiting RAS Nucleotide Cycling as a Strategy for Drugging RAS-Driven Cancers.
Mattox TE; Chen X; Maxuitenko YY; Keeton AB; Piazza GA
Int J Mol Sci; 2019 Dec; 21(1):. PubMed ID: 31878223
[TBL] [Abstract][Full Text] [Related]
13. Role of ERas in promoting tumour-like properties in mouse embryonic stem cells.
Takahashi K; Mitsui K; Yamanaka S
Nature; 2003 May; 423(6939):541-5. PubMed ID: 12774123
[TBL] [Abstract][Full Text] [Related]
14. Farnesyl transferase inhibitors.
Li T; Sparano JA
Cancer Invest; 2008 Aug; 26(7):653-61. PubMed ID: 18665473
[No Abstract] [Full Text] [Related]
15. Improving Prospects for Targeting RAS.
Singh H; Longo DL; Chabner BA
J Clin Oncol; 2015 Nov; 33(31):3650-9. PubMed ID: 26371146
[TBL] [Abstract][Full Text] [Related]
16. Mechanism of free radical nitric oxide-mediated Ras guanine nucleotide dissociation.
Heo J; Prutzman KC; Mocanu V; Campbell SL
J Mol Biol; 2005 Mar; 346(5):1423-40. PubMed ID: 15713491
[TBL] [Abstract][Full Text] [Related]
17. Drug Discovery by Targeting Mutant KRAS.
Ye N
Curr Top Med Chem; 2019; 19(23):2079-2080. PubMed ID: 31762422
[No Abstract] [Full Text] [Related]
18. Direct interaction of Ras and the amino-terminal region of Raf-1 in vitro.
Warne PH; Viciana PR; Downward J
Nature; 1993 Jul; 364(6435):352-5. PubMed ID: 8332195
[TBL] [Abstract][Full Text] [Related]
19. Different structural requirements within the switch II region of the Ras protein for interactions with specific downstream targets.
Moodie SA; Paris M; Villafranca E; Kirshmeier P; Willumsen BM; Wolfman A
Oncogene; 1995 Aug; 11(3):447-54. PubMed ID: 7630628
[TBL] [Abstract][Full Text] [Related]
20. Ras-15A protein shares highly similar dominant-negative biological properties with Ras-17N and forms a stable, guanine-nucleotide resistant complex with CDC25 exchange factor.
Chen SY; Huff SY; Lai CC; Der CJ; Powers S
Oncogene; 1994 Sep; 9(9):2691-8. PubMed ID: 8058333
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
